Inc is a development-stage company that develops, tests and intends to
commercialize solid organ transplantation therapies based on an
approach employing organ-specific precursor tissues. The Company’s
approach involves harvesting embryonic mammalian tissue at appropriate
stages after stem cells have committed to becoming organ-specific
precursor tissues and transplanting them in target human organ systems.
During the fiscal year ended July 31, 2008, the Company did not